乾癬性関節炎に対するTYK2/JAK1 阻害薬, ブレポシチニブの有効性と安全性: フェーズIIb 無作為化対照試験
Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519
Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.
Despite a variety of treatment options, PsA treatment goals of decreasing disease activity, improving HRQoL and function, and preventing structural damage and complications, remain unmet needs.
To help address this, Mease, et al. assessed efficacy and safety of oral brepocitinib in participants with moderate-to-severe PsA for up to 52 weeks.
Keywords:
